BKI1369 is a selective bumped kinase inhibitor (BKI) utilized in medical research, primarily targeting kinases in protozoan parasites such as those causing toxoplasmosis and cryptosporidiosis, as well as fungal pathogens. It is employed to inhibit parasite and fungal growth by disrupting essential signaling pathways, making it valuable for studying infectious diseases and developing antiparasitic and antifungal therapies. Additionally, BKI1369 shows potential in oncology research by inhibiting kinases involved in cancer cell proliferation and survival, aiding in the exploration of signaling pathways and preclinical evaluation of kinase-targeted anticancer treatments. It is also used in biochemical assays to elucidate kinase mechanisms and support novel drug candidate development for both infectious and kinase-related disorders.